welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
NIH Awards $86 Million to Improve Genome Editing Techniques
Somatic Cell Genome Editing support is aimed at improving therapeutic options for both rare and common diseases.
Making changes to a patients DNA can have powerful implications for the treatment of disease. To tap into this immense potential, NIH recently awarded 21 Somatic Cell Genome Editing grants — totaling approximately $86 million over the next five years, pending available funds — to support research aimed at improving methods to edit the human genome. These grants are the first to be awarded through the Somatic Cell Genome Editing (SCGE) program, which was launched in January 2018 with NIH Common Fund support. As a trans-NIH endeavor, SCGE is managed by staff from multiple NIH Institutes and Centers, with leadership from NCATS.
rareRelated
-
Boy with muscular dystrophy writes heartfelt note to Scottish leaderMichael Young, 9, wrote a letter to Scot...
-
Phase 1/2 Study in Boys With Duchenne Muscular DystrophyThe MoveDMD study is a 3-part, Phase 1/2...
-
Santhera’s Raxone® receives first positive EAMS scientific opinion from UK’s MHRA in Duchenne muscular ...The aim of the EAMS is to provide patien...
-
Valeria Ricotti, MD, PhDDr Valeria Ricotti, originally from Ital...
-
Rally for RyanRyan, a 13 year old boy, who lives in th...
-
Safety and Tolerability of Ataluren in a Phase 3 Study of Patients with Nonsense Mutation Duchenne Muscular Dystroph...Objective: Examine the safety/tolerabil...
-
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneThis guidance is not intended to affect ...